Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q1 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

2014 Business Achievements To Date:

• Completed enrollment of pivotal phase 3 trial of Firdapse™ in patients with LEMS
• Raised $26.8 million, net of expenses, in a public offering of shares of common stock
• Retained a Chief Commercial Officer
• Developing and beginning the execution of a comprehensive pre-launch plan
• Announced initiation of an expanded access program which will allow LEMS patients early access to Firdapse™
• Initiated commercial scale manufacturing and process validation to U.S. FDA standards of Firdapse™, in order to build launch supplies prior to the anticipated launch of Firdapse™
• Initiated a safety and tolerance clinical trial of amifampridine phosphate in patients with renal (kidney) impairment
• Recently exhibited at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.

For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.